Enfortumab vedotin – March 2023

• Brand names:
  • Padcev®
• Pharmaceutical Company:
  • Astellas Pharma Australia Pty Ltd
• Condition/Indication: Urothelial cancer
• Meeting Date: March 2023
• Public Summary Document (PSD) November 2022 OOS February 2023 PBAC Meetings - (PDF 762KB)
• Public Summary Document (PSD) November 2022 OOS February 2023 PBAC Meetings - (Word 281KB)

Related Public Summary Documents

• Enfortumab vedotin – November 2022